Abivax Q1 2026 Financial Results and Obefazimod Phase 3 Maintenance Data Update

Abivax SA reported financial results for the first quarter ended March 31, 2026. The company recorded a net loss of €48.5 million, an improvement compared to a €52.4 million loss in Q1 2025. Total operating expenses rose 19% to €57.6 million, primarily driven by a 26% increase in R&D spending (€49.5 million) to support Phase 3 trials for obefazimod in ulcerative colitis (UC) and Phase 2b trials in Crohn’s disease (CD). Financial income significantly increased to €8.0 million, aided by foreign exchange gains and interest on IPO proceeds. Key clinical milestones include the expected top-line 44-week maintenance data for obefazimod in UC in late Q2 2026, with an NDA submission targeted for Q4 2026. Induction data for the ENHANCE-CD trial is also expected in Q4 2026. Post-period, Abivax completed a $90 million repurchase of all outstanding royalty certificates on May 7, 2026, funded by $45 million in cash and $45 million in ADSs. The company also reported positive three-year interim data from its Phase 2a/2b open-label extension trial in UC, showing sustained clinical remission.